Kezar Life Sciences, Inc. (NASDAQ:KZR – Get Rating) was the target of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 2,940,000 shares, a decrease of 14.8% from the April 30th total of 3,450,000 shares. Based on an average daily volume of 1,030,000 shares, the days-to-cover ratio […]
Kezar Life Sciences (NASDAQ:KZR – Get Rating) and Cytokinetics (NASDAQ:CYTK – Get Rating) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, profitability, institutional ownership and valuation. Insider and Institutional Ownership 84.0% of Kezar Life Sciences shares […]
Cytokinetics (NASDAQ:CYTK – Get Rating) and Kezar Life Sciences (NASDAQ:KZR – Get Rating) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk and institutional ownership. Risk and Volatility Cytokinetics has a beta of 0.8, indicating […]
Kezar Life Sciences (NASDAQ:KZR – Get Rating) had its price objective trimmed by HC Wainwright from $21.00 to $19.00 in a research note published on Friday morning, The Fly reports. Separately, William Blair reiterated a market perform rating on shares of Kezar Life Sciences in a research report on Wednesday, March 15th. Kezar Life Sciences […]
Kezar Life Sciences (NASDAQ:KZR – Get Rating) had its price target lowered by Wells Fargo & Company from $14.00 to $13.00 in a research report report published on Friday, The Fly reports. Several other brokerages have also recently weighed in on KZR. HC Wainwright reduced their price objective on Kezar Life Sciences from $21.00 to […]